New combo therapy shows promise for rare blood cancer
NCT ID NCT03863184
First seen Apr 29, 2026 · Last updated Jun 16, 2026 · Updated 11 times
Summary
This study tests a combination of three drugs (acalabrutinib, lenalidomide, and either rituximab or obinutuzumab) in people with untreated mantle cell lymphoma, a rare blood cancer. About 37 adults will receive the treatment for one year, then continue on a lower dose to keep the cancer from coming back. The goal is to see if the combination can make the cancer disappear completely at a microscopic level.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MANTLE CELL LYMPHOMA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Weill Cornell Medicine
New York, New York, 10065, United States
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.